BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boston Scientific Corporation (BSX) Wins Additional EU Approval for Pacemaker


7/30/2012 8:47:32 AM

The Boston Scientific Corp. (NYSE: BSX) implatable pacemaker called Ingenio has received an expanded approval in Europe, which will help the medical device maker expand market share for the product.

Ingenio, which is the first new pacemaker platform launched by Boston Scientific in 10 years, was approved by European regulators in April, and by the U.S. Food and Drug Administration (FDA) in May. This additional approval allows European patients with the pacemaker to undergo MRI scans. Most patients with pacemakers of any kind are not able to have MRIs for other conditions they may have, because the magnets in the MRI machine can interfere with the operation of the pacemaker. Pacemakers are used to treat bradycardia, a condition where the heart beats too slowly.

“The ability to use the Ingenio platform during MRI procedures is a significant advancement to our family of bradycardia devices,” Michael Onuscheck, president of Europe, Middle East and Africa, said in a statement. “This progression in the use of the Ingenio family of pacemakers represents another step in our commitment to expanding our pacing capabilities and improving the lives of patients.”

The Ingenio pacemakers include a technology called RightRate, which is designed to help the heart regulate its rate appropriately during physical activity, and is designed to help patients who feel tired or short of breath after common activities like climbing stairs.

Earlier this year, incoming Boston Scientific CEO Michael Mahoney said increasing the company’s market share in the pacemaker market, which now stands at 15 percent of the $4 billion market, is an important goal for the company.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES